

## **SciBase receives US patent approval for its micro-needle electrodes**

**SciBase, a Swedish medtech company that develops and markets a new technology for early detection of malignant melanoma, has received approval from the United States Patent and Trademark Office (USPTO) for its patent on micro-needle electrodes. This technology is already patented in 12 European countries, Australia and Canada. The patent expires 2023.**

SciBase's point-of-care device Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. Malignant melanoma is a fast growing type of skin cancer, which appears in the epidermis right under the cornified layer. Nevisense's electrodes utilise microscopic needles that permit measurement of the electrical impedance in the skin layers, where malignant melanoma can appear. The technique is essential for detecting the early stages of skin cancer.

"Right now, Nevisense is in the regulatory approval process in the United States, and we see the US as a future key market for us. The approval of this US patent is thus an important step in our coming US expansion. Electrodes with micro-needles can potentially be used to detect other types of cancer as well," says Simon Grant, CEO of SciBase.

SciBase holds a total of 49 registered patents and currently have another 12 active patent applications pending in six patent families.

Skin cancer is the most common cancer in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to age 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75 percent) of deaths related to skin cancer, although it only accounts for 4 percent of all skin cancer cases. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly. The key to management is early detection.

**For more information, please contact:**

Simon Grant, CEO

Phone: +46 72 887 43 99

Email: [simon.grant@scibase.com](mailto:simon.grant@scibase.com)

### **About SciBase and Nevisense**

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. Further information is available on [www.scibase.com](http://www.scibase.com).